CYP19A1 and breast carcinoma: Importantly, however, one of the most exciting results of allosteric mTOR inhibitors in the context of a clinical study was the BOLERO-2 trial, where patients with ER-positive advanced breast cancers resistant to aromatase inhibitors were randomized to receive Exemestane (a non-steroidal aromatase inhibitor) plus Everolimus or Exemestane plus Placebo (Baselga et al., 2012).